NK cell activation by dendritic cell vaccine: A mechanism of action for clinical activity

Cancer Immunology, Immunotherapy

Volumn 55, Issue 9, 2006, Pages 1122-1131

  Osada, Takuya ^a   Clay, Timothy ^a   Hobeika, Amy ^a   Lyerly, H Kim ^a   Morse, Michael A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Dendritic cell; Natural killer cell; Vaccine

Indexed keywords

B7.1 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DENDRITIC CELL VACCINE; GENE PRODUCT; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; RF CEA(6D) TRICOM; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CELL ACTIVATION; CELL ACTIVITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOLYSIS; CYTOTOXICITY; DENDRITIC CELL; DISEASE ACTIVITY; DRUG MECHANISM; FOWLPOX VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOPHARMACOLOGY; IN VITRO STUDY; INNATE IMMUNITY; LUNG CANCER; LYMPHOCYTE ACTIVATION; NATURAL KILLER T CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR IMMUNITY; VACCINATION; VIRUS RECOMBINANT;

ADENOCARCINOMA; CANCER VACCINES; CELLS, CULTURED; COLORECTAL NEOPLASMS; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LUNG NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; TREATMENT OUTCOME;

EID: 33744457009     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0089-3     Document Type: Article

References (28)

1. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK (2005) Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res 11:3017-3024
2. Yokoyama WM, Kim S, French AR (2004) The dynamic life of natural killer cells. Annu Rev Immunol 22:405-429
3. Glas R, Franksson L, Une C, Eloranta ML, Ohlen C, Orn A, Karre K (2000) Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype. An adaptive component of NK cell-mediated responses. J Exp Med 191:129-138
4. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, Perricaudet M, Tursz T, Maraskovsky E, Zitvogel L (1999) Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5:405-411
5. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C (2002) Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 195:343-351
6. Piccioli D, Sbrana S, Melandri E, Valiante NM (2002) Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med 195:335-341
7. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G (2002) Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 195:327-333
8. Raulet DH (2004) Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 5:996-1002
9. Kim A, Noh YW, Kim KD, Jang YS, Choe YK, Lim JS (2004) Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination. Exp Mol Med 36:428-443
10. Parajuli P, Mathupala S, Sloan AE (2004) Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells. Neurosurgery 55:1194-1204
11. Carbone E, Terrazzano G, Ruggiero G, Zanzi D, Ottaiano A, Manzo C, Karre K, Zappacosta S (1999) Recognition of autologous dendritic cells by human NK cells. Eur J Immunol 29:4022-4029
12. Wilson JL, Heffler LC, Charo J, Scheynius A, Bejarano MT, Ljunggren HG (1999) Targeting of human dendritic cells by autologous NK cells. J Immunol 163:6365-6370
13. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchieri G (2005) The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174:727-734
14. van den Broeke LT, Daschbach E, Thomas EK, Andringa G, Berzofsky JA (2003) Dendritic cell-induced activation of adaptive and innate antitumor immunity. J Immunol 171:5842-5852
15. Adam C, King S, Allgeier T, Braumuller H, Luking C, Mysliwietz J, Kriegeskorte A, Busch DH, Rocken M, Mocikat R (2005) DC-NK cell cross-talk as a novel CD4+ T cell-independent pathway for antitumor CTL induction. Blood Mar 15 [Epub ahead of print]
16. Nieda M, Okai M, Tazbirkova A, Lin H, Yamaura A, Ide K, Abraham R, Juji T, Macfarlane DJ, Nicol AJ (2004) Therapeutic activation of Va24+Vb11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103:383-389
17. Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, Beaujean F, Boccaccio C, Zitvogel L, Angevin E (2002) Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 100:2554-2561
18. Fehniger TA, Caligiuri MA (2001) Interleukin 15: biology and relevance to human disease. Blood 97:14-32
19. Cooper MA, Bush JE, Fehniger TA, VanDeusen JB, Waite RE, Liu Y, Aguila HL, Caligiuri MA (2002) In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 100:3633-3638
20. Kalinski P, Giermasz A, Nakamura Y, Basse P, Storkus WJ, Kirkwood JM, Mailliard RB (2005) Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol 42:535-539
21. Assarsson E, Kambayashi T, Schatzle JD, Cramer SO, von Bonin A, Jensen PE, Ljunggren HG, Chambers BJ (2004) NK cells stimulate proliferation of T and NK cells through 2B4/CD48 interactions. J Immunol 173:174-180
22. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19-29
23. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729
24. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732
25. Pende D, Parolini S, Pessino A, Sivori S, Augugliaro R, Morelli L, Marcenaro E, Accame L, Malaspina A, Biassoni R, Bottino C, Moretta L, Moretta A (1999) Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 190:1505-1516
26. Vitale M, Bottino C, Sivori S, Sanseverino L, Castriconi R, Marcenaro E, Augugliaro R, Moretta L, Moretta A (1998) NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J Exp Med 187:2065-2072
27. Sivori S, Vitale M, Morelli L, Sanseverino L, Augugliaro R, Bottino C, Moretta L, Moretta A (1997) p46, a novel natural killer cell-specific surface molecule that mediates cell activation. J Exp Med 186:1129-1136
28. Spaggiari GM, Carosio R, Pende D, Marcenaro S, Rivera P, Zocchi MR, Moretta L, Poggi A (2001) NK cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur J Immunol 31:1656-1665